Commodore Capital’s VistaGen Therapeutics VTGN Stock Holding History

Commodore Capital’s Portfolio VTGN Stock Details VTGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$630K	Buy	+2,788,620	New	+$1.68M	0.04%	33
2025 Q4	–	Sell	-1,575,000	Closed	-$5.59M	–	42
2025 Q3	$5.59M	Hold	1,575,000	–	–	0.27%	36
2025 Q2	$3.15M	Hold	1,575,000	–	–	0.22%	32
2025 Q1	$3.94M	Hold	1,575,000	–	–	0.29%	30
2024 Q4	$4.65M	Hold	1,575,000	–	–	0.34%	28
2024 Q3	$4.74M	Hold	1,575,000	–	–	0.3%	35
2024 Q2	$5.48M	Hold	1,575,000	–	–	0.37%	31
2024 Q1	$8.32M	Hold	1,575,000	–	–	0.56%	32
2023 Q4	$8.1M	Hold	1,575,000	–	–	0.71%	27
2023 Q3	$8.25M	Buy	+1,575,000	New	+$6.99M	0.96%	25
2022 Q3	–	Sell	-434,969	Closed	-$11.5M	–	33
2022 Q2	$11.5M	Buy	434,969 +98,395	+29%	+$3.47M	2.43%	15
2022 Q1	$12.5M	Buy	336,574 +54,407	+19%	+$2.37M	2.8%	13
2021 Q4	$16.5M	Buy	282,167 +111,383	+65%	+$7.25M	3.82%	12
2021 Q3	$14M	Buy	170,784 +59,740	+54%	+$5.19M	3.7%	12
2021 Q2	$10.5M	Sell	111,044 -13,279	-11%	-$984K	3.66%	13
2021 Q1	$7.94M	Buy	124,323 +19,323	+18%	+$1.29M	3.16%	13
2020 Q4	$6.11M	Buy	+105,000	New	+$2.68M	3.32%	16

Other funds holding VTGN

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

AdvisorShares Investments Bethesda, Maryland $828M AUM 37.72% 1-Year Est. Return

Luminus Management Houston, Texas $146M AUM 27.83% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Commodore Capital's VTGN Position: Q2 2026 in Review

Commodore Capital opened a new position in VistaGen Therapeutics (VTGN) in Q2 2026: 2,788,620 shares worth $630K. The stake represents 0.04% of the portfolio and ranks #33 among its holdings. This is a return to the name: Commodore Capital previously reported a position in VTGN as recently as Q3 2025.

Commodore Capital first reported a position in VTGN in Q4 2020 and has held it in 17 quarters since. The position peaked at $16.5M in Q4 2021. 48 funds tracked by Wall St. Rank hold VTGN as of Q2 2026.

Commodore Capital held 2,788,620 shares of VistaGen Therapeutics worth $630K as of Q2 2026.
VistaGen Therapeutics was a new Commodore Capital position in Q2 2026.
VistaGen Therapeutics made up 0.04% of Commodore Capital's portfolio in Q2 2026, its #33 holding.
Commodore Capital first reported a position in VistaGen Therapeutics in Q4 2020 and has held it in 17 quarters since.
Commodore Capital's VistaGen Therapeutics position peaked at $16.5M in Q4 2021.
48 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q2 2026.

Based on Commodore Capital's 13F filing for Q2 2026, filed 14 Aug 2026.